In vitro experiments confirmed their ability to mitigate the inhibition of proliferation and apoptosis in LPS-induced A549 cells.[55] Research by Zhang et al on Shiwei Qingwen decoction indicated that it could alleviate the inflammatory response in acute lung injury by blocking TLR4/NF-κB and NLRP3 inflammasome activation.[56] Xu et al suggested that Yinlai decoction combats pneumonia from pathogens by modifying the pulmonary and systemic environments, with the regulation of the inflammatory factor IL-6 being a potential key target.[57]. Here, NLRP3 is linked to susceptibility to pneumonia measurement.